



**Item 8.01 Other Events.**

Agenus Inc. (“Agenus”) announced today that it has executed three separate transactions, including entering into a definitive agreement to acquire XOMA Corporation’s antibody pilot plant manufacturing facility and capabilities. Additionally, Agenus obtained an exclusive license to a phage display library from IONTAS Limited, and entered into an agreement for cell line development technology with Selexis SA.

The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit No.      Description of Exhibit**

99.1                      Press Release dated November 5, 2015.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 5, 2015 **AGENUS INC.**

By: /s/ C. Evan Ballantyne  
C. Evan Ballantyne  
Chief Financial Officer

---

**EXHIBIT INDEX**

**Exhibit No.   Description of Exhibit**

99.1            Press Release dated November 5, 2015.